Table 1 Characteristics of T1a patients with or without chemotherapy in the whole cohort and matched cohorts
Characteristic | T1a: Whole cohort [cases (%)] | T1a: Matched cohort [cases (%)] | ||||
|---|---|---|---|---|---|---|
Chemotherapy | P-value | Chemotherapy | P-value | |||
No | Yes | No | Yes | |||
GRADE | < 0.01 | 0.87 | ||||
I | 4254 (46.11%) | 128 (15.09%) | 135 (16.03%) | 128 (15.20%) | ||
II | 3906 (42.34%) | 368 (43.40%) | 358 (42.52%) | 366 (43.47%) | ||
III | 1065 (11.54%) | 352 (41.51%) | 349 (41.45%) | 348 (41.33%) | ||
SURGERY | < 0.01 | 0.94 | ||||
Breast-conserving | 6054 (65.63%) | 400 (47.17%) | 393 (46.67%) | 400 (47.51%) | ||
Total mastectomy | 2603 (28.22%) | 353 (41.63%) | 355 (42.16%) | 349 (41.45%) | ||
Modified radical mastectomy | 568 (6.16%) | 95 (11.20%) | 94 (11.16%) | 93 (11.05%) | ||
RADIATION | < 0.01 | 0.66 | ||||
No | 4016 (43.53%) | 466 (54.95%) | 475 (56.41%) | 466 (55.34%) | ||
Yes | 5209 (56.47%) | 382 (45.05%) | 367 (43.59%) | 376 (44.66%) | ||
SUBTYPE | < 0.01 | 0.86 | ||||
HoR + /HER2- | 7766 (84.18%) | 311 (36.67%) | 323 (38.36%) | 311 (36.94%) | ||
HoR + /HER2 + | 621 (6.73%) | 239 (28.18%) | 224 (26.60%) | 239 (28.38%) | ||
HoR-/HER2 + | 302 (3.27%) | 138 (16.27%) | 138 (16.39%) | 135 (16.03%) | ||
HoR-/HER2- | 536 (5.81%) | 160 (18.87%) | 157 (18.65%) | 157 (18.65%) | ||
AGE (year) | < 0.01 | 0.71 | ||||
< 60 | 3818 (41.39%) | 575 (67.81%) | 580 (68.88%) | 573 (68.05%) | ||
≥ 60 | 5407 (58.61%) | 273 (32.19%) | 262 (31.12%) | 269 (31.95%) | ||